Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
Public ClinicalTrials.gov record NCT03732677. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer.
Study identification
- NCT ID
- NCT03732677
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 1,063 participants
Conditions and interventions
Conditions
Interventions
- Cisplatin Drug
- Durvalumab Drug
- Gemcitabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2018
- Primary completion
- Apr 28, 2024
- Completion
- Jun 29, 2026
- Last update posted
- Mar 12, 2026
2018 – 2026
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35294 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | Palo Alto | California | 94304 | — |
| Research Site | New Haven | Connecticut | 06520 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Geneva | Illinois | 60134 | — |
| Research Site | Iowa City | Iowa | 52242 | — |
| Research Site | Westwood | Kansas | 66205 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | New Orleans | Louisiana | 70112 | — |
| Research Site | Towson | Maryland | 21204 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | New York | New York | 10029 | — |
| Research Site | Rochester | New York | 14642 | — |
| Research Site | Bethlehem | Pennsylvania | 18015 | — |
| Research Site | Burlington | Vermont | 05401 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 170 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03732677, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2026 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03732677 live on ClinicalTrials.gov.